Ron Maddux retweeted
Who wants a Craft&Ride Rug? Here’s how to enter to win:
1️⃣ Like this tweet.
2️⃣ Retweet this tweet.
Giveaway ends tonight at 11:59 PM PT. Winner will be announced tomorrow, March 15th.
Ron Maddux retweeted
One retweeter will get a mystery Halloween pack shipped by us directly to them! Member, or non member. Happy Halloween!🎃
Ron Maddux retweeted
The CliniMACS Cell Factory brings commercial-scale cell manufacturing to the next level. Our scalable, automated and closed system cell processing platform reduces cleanroom requirements + enables parallel manufacturing on multiple instruments in one room: ow.ly/EDVe50wbjJg
Ron Maddux retweeted
On this date in #History 1st ever pt treated w gene modified cells by Steve Rosenberg et al. @NIH #celltherapy
Ron Maddux retweeted
Have you registered for our exclusive live webinar with @RegMedNet yet? Join us on Feb 21 to learn more about our solutions for automated, large-scale, and GMP-compliant cell manufacturing. ow.ly/yUs730nxBMA
Ron Maddux retweeted
Register for our webinar in association with @miltenyibiotec which will show you how to implement GMP-compliant and scalable manufacturing of different adherent cell types, such as pluripotent stem cells and their derivatives https://teapawt.net/t.co/oXXLSzSTXC
Ron Maddux retweeted
Join this @RegMedNet webinar on February 21 and get to know our solutions for automated, large-scale, and GMP-compliant manufacturing of adherent cell types. Register here ow.ly/yUs730nxBMA
Ron Maddux retweeted
February 4 is #WorldCancerDay. Join us and show support, raise awareness, and take action. #IAmAndIWill
Ron Maddux retweeted
Hey @THEMADDUX you were the star of #phacilitate2019 . Larger than life poster of you above the networking village #thatshowyouknowyouvemadeit – at Washington, DC
Ron Maddux retweeted
HUUUGE – at Washington, DC
Congrats to the FDA for developing novel guidelines for cell and gene therapy!
fdanews.com/articles/190041-…
Ron Maddux retweeted
Dr Crystal Mackall @StanfordMed delivers the Abelson lecture @seattlechildren this morning- highlighting new approaches for immunotherapy of childhood cancer
Ron Maddux retweeted
Big news! Accrual complete on #BMTCTN 1301 (PROGRESS II; CNI-Free GVHD Prophy)! Thx to PIs, coords, lab & study staff for your commitment to this trial. Most importantly, thanks to patients that participated!
Now time to make some more progress...PROGRESS III (PTCy vs. Tac/Mtx)!
Ron Maddux retweeted
We’ve arrived at #EBMT18. Join us at booth 1 to discover our latest innovations in CAR T #celltherapy and learn more about our CARAT fellowship program. Plus, don’t miss our CARAT session tomorrow at 3pm. goo.gl/KFLGvj
Ron Maddux retweeted
We’re happy to announce that EMA has approved the first commercial #celltherapy manufacturing process on the #CliniMACSProdigy. This is an important step towards automation of personalized cell therapy. goo.gl/N5Y5tX
Ron Maddux retweeted
Dual CARs moving forward @MCW congrats to @Phari Nirav Shah, Carolyn K-Taylor and the @Miltenyi team stories.mcw.edu/stories/car-…
Ron Maddux retweeted
Accrual update: 279 patients enrolled on #BMTCTN 1301 (PROGRESS II; CNI-Free GVHD Prophy); accrual 80% complete!
clinicaltrials.gov/ct2/show/…
Ron Maddux retweeted
Use of banked virus-specific T cells to treat BK virus, HHV-6, CMV, EBV, and adenovirus after allogeneic HSCT https://teapawt.net/t.co/2yR9BhqGR3
Ron Maddux retweeted
CAR-T Cell Therapy Is Here To Stay lnkd.in/d2H7Nsm





















